Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Cancer Treatment Reviews|June 1, 2025
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progressionRoberto Buonaiuto, Andrea Botticelli, Carmen Criscitiello, et al.
Oncotarget|September 17, 2016
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancerLuca Malorni, Silvano Piazza, Yari Ciani, et al.
BMC Genomics|December 26, 2018
ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq dataDario Romagnoli, Giulia Boccalini, Martina Bonechi, et al.
Oncogene|January 16, 2003
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenesMaria Domenica Castellone, Anna Maria Cirafici, Gabriella De Vita, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 10, 2009
Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysisMaddalena Barba, Li Yang, Holger J Schünemann, et al.
Breast Cancer Research and Treatment|November 20, 2009
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerIlenia Migliaccio, Meng-Fen Wu, Carolina Gutierrez, et al.
Breast Cancer Research and Treatment|March 23, 2018
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patientsEmanuela Risi, Andrea Grilli, Ilenia Migliaccio, et al.
Frontiers in Oncology|August 10, 2019
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeAmelia McCartney, Ilenia Migliaccio, Martina Bonechi, et al.
Cells|March 14, 2020
Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib.Nicla Lorito, Marina Bacci, Alfredo Smiriglia, et al.
Oncotarget|April 18, 2018
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapyMartina Bonechi, Francesca Galardi, Chiara Biagioni, et al.
Pageof 7